QAX576
Sponsors
Novartis, Novartis Pharmaceuticals
Conditions
Allergic RhinitisAsthmaCrohn's DiseaseEosinophilic EsophagitisHealthyIdiopathic Pulmonary FibrosisKeloidsPulmonary Fibrosis Secondary to Systemic Sclerosis
Phase 1
Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.
CompletedNCT00417196
Start: 2006-12-31End: 2007-08-31Updated: 2010-10-01
Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma
WithdrawnNCT00598104
Start: 2008-01-31Updated: 2016-03-04
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients
CompletedNCT00940160
Start: 2009-07-31Updated: 2020-12-21
To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma
CompletedNCT01568762
Start: 2010-10-31Updated: 2020-12-21
Phase 2
SD, IL-13 Production Rate in IPF
CompletedNCT00532233
Start: 2007-09-30End: 2009-06-30Updated: 2020-12-19
QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
TerminatedNCT00581997
Start: 2007-12-31Updated: 2020-12-19
An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever
CompletedNCT00584584
Start: 2007-12-31Updated: 2017-02-24
Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence
TerminatedNCT00987545
Start: 2009-06-30End: 2010-11-30Updated: 2020-12-19
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
CompletedNCT01022970
Start: 2009-11-30Updated: 2021-03-11
Efficacy of QAX576 in Asthma
CompletedNCT01130064
Start: 2010-05-31End: 2012-04-30Updated: 2020-12-19
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
TerminatedNCT01266135
Start: 2010-12-31End: 2013-04-30Updated: 2020-12-19
A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients
CompletedNCT01355614
Start: 2011-06-30End: 2013-03-31Updated: 2017-02-23